Orchestra BioMed Holdings (OBIO) Gains from Sales and Divestitures (2023 - 2025)
Historic Gains from Sales and Divestitures for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Q3 2025 value amounting to $922848.0.
- Orchestra BioMed Holdings' Gains from Sales and Divestitures rose 53830.9% to $922848.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $922848.0, marking a year-over-year increase of 53830.9%. This contributed to the annual value of $416368.0 for FY2024, which is 41537.07% up from last year.
- As of Q3 2025, Orchestra BioMed Holdings' Gains from Sales and Divestitures stood at $922848.0, which was up 53830.9% from $625414.0 recorded in Q2 2025.
- In the past 5 years, Orchestra BioMed Holdings' Gains from Sales and Divestitures ranged from a high of $922848.0 in Q3 2025 and a low of $13100.0 during Q1 2024
- Over the past 3 years, Orchestra BioMed Holdings' median Gains from Sales and Divestitures value was $112683.5 (recorded in 2023), while the average stood at $253482.5.
- Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 6485.16% in 2024, then soared by 270429.56% in 2025.
- Orchestra BioMed Holdings' Gains from Sales and Divestitures (Quarter) stood at $80790.0 in 2023, then soared by 415.37% to $416368.0 in 2024, then surged by 121.64% to $922848.0 in 2025.
- Its Gains from Sales and Divestitures was $922848.0 in Q3 2025, compared to $625414.0 in Q2 2025 and $178286.0 in Q1 2025.